Memory-Efficient Intrinsic Gating Adaptation for Enhanced On-Device Epilepsy Diagnosis
IEEE Journal of Biomedical and Health Informatics
|December 15, 2025
Summary
This study introduces Memory-Efficient Intrinsic Gating Adaptation (MEIGA) for improved epilepsy diagnosis using EEG data on edge devices. MEIGA enhances seizure prediction and detection accuracy by efficiently adapting to patient biomarker variations.
Area of Science:
- Neuroscience
- Artificial Intelligence
- Biomedical Engineering
Background:
- Epilepsy diagnosis relies on Electroencephalogram (EEG) but faces challenges due to patient-specific biomarker variability and resource constraints on edge devices.
- Conventional deep learning models struggle to adapt to changing biomarkers over time, leading to decreased diagnostic performance.
- On-device learning for epilepsy diagnosis is hindered by computational and memory limitations.
Purpose of the Study:
- To introduce a novel framework, Memory-Efficient Intrinsic Gating Adaptation (MEIGA), for efficient and accurate epilepsy diagnosis on resource-constrained edge devices.
- To address session-to-session variability in EEG biomarkers through lightweight adapter networks for on-device tuning.
- To reduce memory usage and computational overhead while maintaining high classification accuracy in seizure detection and prediction.
Main Methods:
- Pre-training a model on historical EEG data and employing lightweight adapter networks for efficient on-device tuning.
- Utilizing Direct Feedback Alignment (DFA) to minimize memory and computational requirements.
- Evaluating the framework on the CHB-MIT and AES epilepsy datasets.
Main Results:
- MEIGA significantly improved seizure prediction accuracy from 47.88% to 86.77% with minimal tunable parameters (5.05% of the backbone).
- Seizure detection accuracy increased from 85.06% to 96.29% by adapting only 17.40% of the base architecture.
- The framework demonstrated consistent performance across subjects and scalability on the AES dataset.
Conclusions:
- MEIGA offers an effective solution for real-world epilepsy diagnosis on edge devices, overcoming limitations of traditional deep learning models.
- The proposed method enhances diagnostic accuracy and efficiency by adapting to individual patient biomarker changes.
- MEIGA presents a promising approach for advancing accessible and reliable epilepsy monitoring systems.
Related Concept Videos
Epilepsy and Seizures: Overview
1.1K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
Seizures: Classification
1.3K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.3K
Antiepileptic Drugs: Potassium Channel Activators
603
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
603


